In addition, Jones and coworkers (2019) identified the pan-HDAC inhibitor pracrinostat, approved in 2014 as an orphan drug for AML, as a potent attenuator of lung fibroblast activation in IPF patient-derived fibroblasts [246]. The gene discussed is HDAC9; the disease is idiopathic pulmonary fibrosis.